Current and Emerging Therapies for Lysosomal Storage Disorders
Related Experiment Video
Updated: Jun 1, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Diego Agustín Abelleyra Lastoria1, Sophie Keynes1, Derralynn Hughes2
1Institute for Medical and Biomedical Education, St George's, University of London, London, SW17 0RE, UK.
Abstract:
Lysosomal storage disorders (LSDs) are rare inherited metabolic disorders characterized by defects in the function of specific enzymes responsible for breaking down substrates within cellular organelles (lysosomes) essential for the processing of macromolecules. Undigested substrate accumulates within lysosomes, leading to cellular dysfunction, tissue damage, and clinical manifestations. Clinical features vary depending on the degree and type of enzyme deficiency, the type and extent of substrate accumulated, and the tissues affected. The heterogeneous nature of LSDs results in a variety of treatment approaches, which must be tailored to patient presentation and characteristics. The treatment landscape for LSDs is rapidly evolving. An up-to-date discussion of current evidence is required to provide clinicians with an appropriate overview of treatment options. Therefore, we aimed to review current and ongoing trials pertaining to the treatment of common LSDs.
Related Concept Videos
Lysosomal Hydrolases
Delivery Pathways to the Lysosome
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Lysosomes
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drug Therapy
Antianxiety Medications

